VASO Corporation reported a 2.7% revenue increase to $89.1 million in 2025 driven mainly by its professional sales service segment. However, the IT segment saw a significant swing to an operating loss due largely to goodwill impairment, while the proprietary equipment segment also posted a slight operating loss. The company’s financial performance is heavily dependent on its exclusive sales relationship with GE HealthCare Technologies, contributing roughly half of revenues and all reported operating income. Looking ahead, sustaining growth hinges on the continuation of this agreement, increased penetration of GEHC products, and successful expansion of medical device offerings amid competitive and regulatory pressures. Capital allocation remains conservative with no dividends or share repurchases indicated, supported by solid cash flow generation despite recent profitability volatility.